At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 397 enrolled
Drug / intervention
GSK3511294 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
In Brief
A Phase 3 clinical trial evaluating GSK3511294 and Placebo for Asthma. Completed, enrolled 397 participants across 129 sites in 11 countries.
Detailed Summary
This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesAustralia, Canada, Czechia, France, Hungary, Italy, Japan, Poland, Spain, Taiwan, United States
CollaboratorsIQVIA Pty Ltd
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartFeb 2021
Primary CompletionApr 2024
TodayJul 2026
First PostedJan 22, 2021
Enrollment StartFeb 4, 2021
Primary CompletionApr 11, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.4 years ago
Interventions
GSK3511294biological
GSK3511294 was administered using a pre-filled syringe.
Placebobiological
Placebo was administered as normal saline using a pre-filled syringe.